Dupixent significantly reduced COPD exacerbations in second positive Phase 3 trial
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Subscribe To Our Newsletter & Stay Updated